NovaBone Products launched NovaBone IRM and NovaBone IRM MacroPOR to its portfolio of biologically-active bone graft substitutes.
Both formulations are designed to optimize osteogenesis, stimulate osteoblastic activity and offer angiogenic potential. The products are highly resistant to irrigation and designed with high-performing cohesion and handling properties.
Novabone’s portfolio of bioactive synthetic bone graft subs include minimally invasive delivery devices such as the MacroFORM MIS ready-to-use cannula and strip/ready-to-use putty formulations.
NovaBone Products launched NovaBone IRM and NovaBone IRM MacroPOR to its portfolio of biologically-active bone graft substitutes.
Both formulations are designed to optimize osteogenesis, stimulate osteoblastic activity and offer angiogenic potential. The products are highly resistant to irrigation and designed with high-performing cohesion and...
NovaBone Products launched NovaBone IRM and NovaBone IRM MacroPOR to its portfolio of biologically-active bone graft substitutes.
Both formulations are designed to optimize osteogenesis, stimulate osteoblastic activity and offer angiogenic potential. The products are highly resistant to irrigation and designed with high-performing cohesion and handling properties.
Novabone’s portfolio of bioactive synthetic bone graft subs include minimally invasive delivery devices such as the MacroFORM MIS ready-to-use cannula and strip/ready-to-use putty formulations.
Copy to clipboard 
